par Boyle, Frances;Moy, Beverly;Finkelstein, Dianne D.M.;Goss, Paul E;Smith, Ian I.E.;O'Shaughnessy, Joyce;Ejlertsen, Bent;Buzdar, Aman;Fumoleau, Pierre;Gradishar, William;Martin, Miguel;Piccart-Gebhart, Martine ;Pritchard, Kathleen;Lindquist, Deborah;Amonkar, Mayur;Huang, Yingjie;Rappold, Erica;Williams, Lisa L.S.;Wang-Silvanto, Jing;Kaneko, Tomomi
Référence European journal of cancer, 51, 6, page (685-696)
Publication Publié, 2015
Référence European journal of cancer, 51, 6, page (685-696)
Publication Publié, 2015
Article révisé par les pairs
Titre: |
|
Auteur: | Boyle, Frances; Moy, Beverly; Finkelstein, Dianne D.M.; Goss, Paul E; Smith, Ian I.E.; O'Shaughnessy, Joyce; Ejlertsen, Bent; Buzdar, Aman; Fumoleau, Pierre; Gradishar, William; Martin, Miguel; Piccart-Gebhart, Martine; Pritchard, Kathleen; Lindquist, Deborah; Amonkar, Mayur; Huang, Yingjie; Rappold, Erica; Williams, Lisa L.S.; Wang-Silvanto, Jing; Kaneko, Tomomi |
Informations sur la publication: | European journal of cancer, 51, 6, page (685-696) |
Statut de publication: | Publié, 2015 |
Sujet CREF: | Cancérologie |
Mots-clés: | Adjuvant breast cancer |
Chemotherapy (TEACH) trial | |
Early breast cancer | |
Evaluation After | |
Growth Factor Receptor (HER2) | |
Health related quality of life | |
HER2 positive | |
HRQOL | |
Human Epidermal | |
Lapatinib | |
Placebo | |
SF-36 | |
Tykerb/Tyverb | |
Note générale: | SCOPUS: cp.j |
Langue: | Anglais |
Identificateurs: | urn:issn:0959-8049 |
info:doi/10.1016/j.ejca.2015.02.005 | |
info:pii/S0959804915001689 | |
info:scp/84925372286 |